OvaGene Oncology opens new advanced molecular research and clinical laboratory facility

OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California.  This state-of-the-art facility will serve as the central headquarters for operations, research, and molecular clinical lab testing.  

The opening of the laboratory is an important first step for OvaGene Oncology.  The new facility will allow the company to perform genomic testing on cancer cells using advanced technologies such as Quantitative Polymerase Chain Reaction (QPCR), Comparative Genomic Hybridization (CGH) and Gene Expression Arrays. OvaGene is currently in the process of pursuing clinical laboratory licensure (CLIA) and accreditation (CAP) and will begin offering several non-proprietary molecular diagnostics to the gynecologic oncology community once approvals have been obtained.  

In addition to clinical laboratory testing, a series of proprietary diagnostics based on in-licensed technologies and internal research will be developed at the new facility. OvaGene's research will include collaborations with key pharmaceutical companies in the oncology space with the goal of developing companion diagnostics.  

"This advanced molecular research and clinical laboratory facility is the foundation for OvaGene's creativity, science and treatment-related innovation. It puts OvaGene at the forefront of the application of gene-based technologies within the field of gynecologic oncology," said President and CEO Frank Kiesner.  Mr. Kiesner added, "It is OvaGene's mission to provide physicians treating gynecologic cancers with novel gene-based assays to individualize patient diagnosis, staging and drug selection in a manner not possible through existing non-gene-based technologies."

SOURCE OvaGene Oncology Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research reveals only a few brain regions remain untouched by transition to motherhood